Abstracts tagged "Abatacept"

Abstract Number: 2740 • 2015 ACR/ARHP Annual Meeting
ACPA Positivity in the Elderly and Concomitant MTX Use in Younger May be Useful Predictive Factors for Superior Clinical Efficacy with Abatacept in Japanese Biological-Naïve RA Patients
Masahiro Sekiguchi¹, Takao Fujii², Masayasu Kitano¹, Kiyoshi Matsui¹, Kenji Miki³, Hideo Hashimoto⁴, Akira Yokota⁵, Aihiro Yamamoto⁶, Takashi Fujimoto⁷, Toshihiko Hidaka⁸, Naoki Shimmyo⁹, Keiji Maeda¹⁰, Takanori Kuroiwa¹¹, Ichiro Yoshii¹², Kosaku Murakami¹³, Koichiro Ohmura¹³, Satoshi Morita¹⁴, Yutaka Kawahito⁶, Norihiro Nishimoto¹⁵, Tsuneyo Mimori¹⁶ and Hajime Sano¹, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Dept of Rheum/Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁴Rheumatology, Rinku Hashimoto Rheumatology Orthopaedics, Izumisano Osaka, Japan, ⁵Yokota Clinic for Rheumatology, Osaka, Japan, ⁶Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁷Nara Medical University, Kashihara, Japan, ⁸Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ⁹Department of Rheumatology, Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹⁰Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ¹¹Department of Internal Medicine, Yukioka Hospital, Osaka, Japan, ¹²Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹³Rheumatology & Clin Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁴Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ¹⁵Osaka Rheumatology Clinic, Osaka, Japan, ¹⁶Dept of Rheum & Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Sustained clinical remission is crucial in the RA. However, baseline predicting factors for sustained clinical remission in RA patients treated with abatacept (ABT) are…
Abstract Number: 547 • 2015 ACR/ARHP Annual Meeting
Abatacept Does Not Improve Subclinical Atherosclerosis Despite Good Response in Rheumatoid Arthritis: A Cohort Study
Kensuke Kume¹, Kanzo Amano^1,2, Susumu Yamada¹, Toshikatsu Kanazawa³, Kazuhiko Hatta⁴, Kuniki Amano⁵ and Noriko Kuwaba⁶, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Rheumatology, Sky Clinic, Hiroshima, Japan, ⁶Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Abatacept (ABT) is very effective in treating rheumatoid arthritis(RA)1. Patients with RA have an increased risk of cardiovascular disease (CVD), and rheumatologists need to…
Abstract Number: 2766 • 2015 ACR/ARHP Annual Meeting
Glucocorticoid-Sparing Effects of Abatacept in Real Life Practice: Data from a Paneuropean Analysis of RA Registries
Jacques Gottenberg¹, Xavier Mariette², Maria Victoria Hernandez³, Florenzo Iannone⁴, Elisabeth Lie⁵, Helena Canhão⁶, Karel Pavelka⁷, Carl Turesson⁸, Merete Lund Hetland⁹ and Axel Finckh¹⁰, ¹Hautepierre, Strasbourg, France, ²Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³Biobadaser, Barcelona, Spain, ⁴Bari University, Rheumatology, Bari, Italy, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Lisbonne, Portugal, ⁷Charles University, Prague, Czech Republic, ⁸Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ⁹DANBIO, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ¹⁰Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland
Background/Purpose: Despite disease modifying anti-rheumatic drugs (bDMARDs), glucocorticoids (GCs) are still widely prescribed in rheumatoid arthritis (RA). GCs are associated with numerous potential side effects,…
Abstract Number: 560 • 2015 ACR/ARHP Annual Meeting
Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept
Leslie Harrold^1,2, KK Gandhi³, H Litman⁴, S Kelly³, YF Li⁵, E Alemao³, S Deveikis⁴ and J Greenberg^1,6, ¹Corrona, LLC, Southborough, MA, ²Dept of Medicine, University of Massachusetts Medical School, Worcester, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Response to therapies may vary based on anti-citrullinated protein antibodies (ACPA) status. We compared treatment response to abatacept in ACPA-positive versus -negative RA patients…
Abstract Number: 2774 • 2015 ACR/ARHP Annual Meeting
Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Rossella Reggia¹, Ilaria Cavazzana¹, Angela Tincani² and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Abatacept is a selective T cell costimulation modulator indicated for active Rheumatoid Arthritis (RA). Since August 2013, in Italy, the drug has also been…
Abstract Number: 563 • 2015 ACR/ARHP Annual Meeting
Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis
Paul Emery¹, G Burmester², VP Bykerk³, B Combe⁴, Daniel E. Furst⁵, M Maldonado⁶ and T. W. J. Huizinga⁷, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, New York, NY, ⁴Service d’Immuno-Rheumatologie, Montpellier, France, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Assessing Very Early Rheumatoid arthritis Treatment (AVERT) was a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of abatacept (ABA) treatment…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
Abstract Number: 2486 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis
Daniel E. Furst¹, Vivian P. Bykerk², Gerd Burmester³, B Combe⁴, T W J Huizinga⁵, E Alemao⁶, D Wong⁶, C S Karyekar⁶ and P Emery⁷, ¹University of California at Los Angeles, Los Angeles, CA, ²Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Monpellier University Hospital, Montpellier, France, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Early biologic use can improve long-term control of RA,1,2 potentially leading to improved physical function and reduced pain. Recent EULAR recommendations support shared decisions…
Abstract Number: 512 • 2014 ACR/ARHP Annual Meeting
Effect and Safety of Concomitant Methotrexate and Tacrolimus on Clinical Response of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Biological Dmards
Nobunori Takahashi¹, Toshihisa Kojima¹, Yuji Hirano², Yasuhide Kanayama³, Koji Funahashi⁴ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ³Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose Abatacept (ABT) is a new class of biologic agents for the treatment of rheumatoid arthritis (RA) that inhibits T cell activation by binding to…
Abstract Number: 2468 • 2014 ACR/ARHP Annual Meeting
Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis
Gerd Burmester¹, Daniel E. Furst², B G Combe³, T W J Huizinga⁴, Vivian P. Bykerk⁵, D Wong⁶, C S Karyekar⁶ and P Emery⁷, ¹Charité – University Medicine Berlin, Berlin, Germany, ²University of California at Los Angeles, Los Angeles, CA, ³Montpellier University Hospital, Montpellier, France, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Clinical remission is associated with better long-term outcomes1,2 and should be the goal of therapy in RA. In the Assessing Very Early Rheumatoid arthritis…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
Abstract Number: 2151 • 2014 ACR/ARHP Annual Meeting
Abatacept Related Infections: No Association with Gammaglobulin Reduction
Valquiria Dinis¹, Vilma S. T. Viana¹, Elaine P. Leon¹, Clovis A Silva², Carla G.S. Saad³, Julio C. B. Moraes³, Eloisa Bonfá³ and Ana C.M. Ribeiro⁴, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose A recent study reported that abatacept (ABA) reduces rheumatoid arthritis (RA) related autoantibodies and gammaglobulins levels. However, the possible association of these findings with…
Abstract Number: 472 • 2014 ACR/ARHP Annual Meeting
Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease
Shinji Motojima¹, Tamao Nakashita², Akira Jibatake³ and Katsutoshi Ando⁴, ¹[email protected], Kameda Medical Center, Kamogawa City, Japan, ²[email protected], Kameda Medical Center, Kamogawa-city, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ⁴Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan
Background/Purpose : Interstitial lung disease (ILD) associated with RA is a big concern particularly in Japanese patients evidenced by the reports that the cause of…
Abstract Number: 1966 • 2014 ACR/ARHP Annual Meeting
CTLA4-Ig (abatacept) Modulate in Vitro the ICAM1 and VEGFR-2 Expression in Human Endothelial Cells
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano², Paola Contini³, Barbara Villaggio⁴, Alberto Sulli¹, Sabrina Paolino¹, Carmen Pizzorni¹, Bruno Seriolo¹, Giuseppe Zampogna², Marco A. Cimmino¹ and Renata Brizzolara², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ³Division of Clinical Immunology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁴Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy
Background/Purpose CTLA4-Ig (abatacept) is employed as biological agent in rheumatoid arthtritis (RA) treatment and interacts with the costimulatory molecule CD86 expressed by different cells involved…
Abstract Number: 328 • 2014 ACR/ARHP Annual Meeting
Etanercept, Abatacept and Anakinra Treatment Ameliorates Inflammation and Pain in a Novel Mono-Arthritic Multi-Flare Model of Streptococcal Cell Wall Induced Arthritis: Further Characterization in a Rodent Model of Collagen Induced Arthritis
Kalyan Chakravarthy¹, Robert Faltus¹, Anwar Murtaza¹ and Milenko Cicmil², ¹Pharmacology, Merck Research Laboratories, Boston, MA, ²Merck Research Laboratories, Boston, MA
Background/Purpose: We developed a novel mono-arthritic multi-flare Rat Streptococcal Cell Wall (SCW) model which captures certain aspects of disease with flares and remission of inflammation…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].